A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Analytical Biochemistry

• Publication date

  2001-09-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1006/ABIO.2001.5316PMID 11554720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasminogen Activator Inhibitor-1 and Its Cofactor Vitronectin Stabilize Arterial Thrombi After Vascular Injury in Mice

  2001cited by this paper
• Characterization of a complex between active plasminogen activator inhibitor-1 and N-terminal fragments of vitronectin from human placenta

  2000cited by this paper
• New Insights into the Size and Stoichiometry of the Plasminogen Activator Inhibitor Type-1·Vitronectin Complex*

  2000cited by this paper
• Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.

  2000cited by this paper
• Regulation of cell adhesion by PAI‐1

  1999cited by this paper
• Vitronectin inhibits the thrombotic response to arterial injury in mice.

  1999cited by this paper
• Binding sites on native and multimeric vitronectin exhibit similar affinity for heparin the influence of self-association and multivalence on ligand binding.

  1998cited by this paper
• Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing.

  1998cited by this paper
• The adipocyte and hemostatic balance in obesity: studies of PAI-1.

  1998cited by this paper
• Role of vitronectin and its receptors in haemostasis and vascular remodeling.

  1998cited by this paper
• Of mice and men. The function of plasminogen activator inhibitors (PAIs) in vivo.

  1997cited by this paper
• Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system

  1997cited by this paper
• Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.

  1997cited by this paper
• Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

  1997cited by this paper
• Structural and Functional Analysis of the Plasminogen Activator Inhibitor-1 Binding Motif in the Somatomedin B Domain of Vitronectin*

  1996cited by this paper
• The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.

  1996cited by this paper
• The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin

  1996cited by this paper
• Type 1 Plasminogen Activator Inhibitor Induces Multimerization of Plasma Vitronectin

  1996cited by this paper
• The urokinase receptor is a major vitronectin-binding protein on endothelial cells.

  1996cited by this paper
• Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

  1996cited by this paper
• The PAI-1/Vitronectin Interaction: Two Cats in a Bag?

  1995cited by this paper
• Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update

  1995cited by this paper
• The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.

  1994cited by this paper
• Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin.

  1993cited by this paper
• Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin

  1993cited by this paper
• Structural basis of latency in plasminogen activator inhibitor-1

  1992cited by this paper
• Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.

  1992cited by this paper
• Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.

  1992cited by this paper
• Studies on the interaction between plasminogen activator inhibitor-1 and vitronectin

  1992cited by this paper
• Regulation of PAI-1 gene expression

  1991cited by this paper
• Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.

  1991cited by this paper
• High resolution analysis of functional determinants on human tissue-type plasminogen activator.

  1991cited by this paper
• A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor.

  1991cited by this paper
• Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin.

  1991cited by this paper
• Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.

  1990cited by this paper
• Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor

  1990cited by this paper
• Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin.

  1989cited by this paper
• Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin.

  1989cited by this paper
• Novel purification of vitronectin from human plasma by heparin affinity chromatography.

  1988cited by this paper
• Hemostasis and thrombosis: Basic principles and clinical practice

  1987cited by this paper
• Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

  1986cited by this paper
• Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin.

  1985cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper

• Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

  2020cites this paper
• CROSS-TALK BETWEEN THE PROTEOLYTIC AND NON-PROTEOLYTIC FUNCTIONS OF THE UROKINASE RECEPTOR

  2015cites this paper
• Studies on the Role of Vitronectin and Plasminogen-Activator Inhibitor-1 Complexes Beyond Inhibiting Proteases: Binding to the Extracellular Matrix, Cell Interactions and Pathogenesis

  2010cites this paper
• The PAI-1-vitronectin-vimentin ternary complex : mechanism of extracellular assembly and role in transplant vasculopathy

  2008cites this paper
• Characterization of Vitronectin and Plasminogen Activator Inhibitor Type 1: Insights into Metal Binding, and Production of Reagents to Facilitate Structural Studies

  2008cites this paper
• Defining the Native Disulfide Topology in the Somatomedin B Domain of Human Vitronectin*

  2007cites this paper
• Vitronectin and Plasminogen Activator Inhibitor-1 Form Higher-Order Complexes that Localize to the Extracellular Matrix and Adopt Adhesive Properties

  2006cites this paper
• The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.

  2006cites this paper
• Serpin-ligand interactions.

  2004cites this paper
• Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin.

  2004cites this paper
• Binding and fate of plasminogen activator inhibitor type-2 in breast carcinoma cells: rationale for development as a delivery vehicle of cytotoxins for anti-urokinase therapeutic strategies

  2004cites this paper
• Random Peptide Bacteriophage Display as a Probe for Urokinase Receptor Ligands

  2002cites this paper
• Identification of the Disulfide Bonds in the Recombinant Somatomedin B Domain of Human Vitronectin*

  2002cites this paper
• Kinetic Analysis of the Interaction between Vitronectin and the Urokinase Receptor*

  2002cites this paper
• Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.

  2002cites this paper
• Interaction of Plasminogen Activator Inhibitor Type-1 (PAI-1) with Vitronectin (Vn): Mapping the Binding Sites on PAI-1 and Vn

  2002cites this paper